BACKGROUND: Screening-CT is able to discover small peripheral lung nodules. The nature of these nodules is uncertain but it is reasonable that some of them, in particular the non-solid ones, could represent precancerous lesions. A previous trial showed a reduction in size of peripheral nodules by inhaled budesonide in subjects with bronchial dysplasia. OBJECTIVE: The primary objective of the study was the evaluation of the effect of budesonide as a chemopreventive agent for lung lesions. The primary endpoint was the modification of lung lesions at ld-CT scan (according to RECIST criteria) after one year of treatment in a person-specific analysis. METHODS: We performed a randomized, double-blind, placebo controlled trial to evaluate whether inhaled budesonide was able to reduce size and number of persistent, undetermined CT-detected lung nodules in high-risk asymptomatic subjects currently undergoing a five-year CT scan screening program at the European Institute of Oncology. RESULTS:Trial enrollment started in April 2006 and ended in July 2007 with the randomization of 202 current or former smokers with stable CT-detected lung nodules set to receivebudesonide 800 μg or placebo twice daily for 12 months. CONCLUSION: Our trial represents the first phase II study of a chemopreventive intervention focusing on the peripheral lung, where the majority of lung cancers arise. The research was nested into a screening project with clear advantages in participant accrual and reduction of costs. This paper describes the rationale and design of the study, thus focusing on the methodology and operational aspects of the clinical trial. (Clinicaltrials.gov number. NCT00321893).
RCT Entities:
BACKGROUND: Screening-CT is able to discover small peripheral lung nodules. The nature of these nodules is uncertain but it is reasonable that some of them, in particular the non-solid ones, could represent precancerous lesions. A previous trial showed a reduction in size of peripheral nodules by inhaled budesonide in subjects with bronchial dysplasia. OBJECTIVE: The primary objective of the study was the evaluation of the effect of budesonide as a chemopreventive agent for lung lesions. The primary endpoint was the modification of lung lesions at ld-CT scan (according to RECIST criteria) after one year of treatment in a person-specific analysis. METHODS: We performed a randomized, double-blind, placebo controlled trial to evaluate whether inhaled budesonide was able to reduce size and number of persistent, undetermined CT-detected lung nodules in high-risk asymptomatic subjects currently undergoing a five-year CT scan screening program at the European Institute of Oncology. RESULTS: Trial enrollment started in April 2006 and ended in July 2007 with the randomization of 202 current or former smokers with stable CT-detected lung nodules set to receive budesonide 800 μg or placebo twice daily for 12 months. CONCLUSION: Our trial represents the first phase II study of a chemopreventive intervention focusing on the peripheral lung, where the majority of lung cancers arise. The research was nested into a screening project with clear advantages in participant accrual and reduction of costs. This paper describes the rationale and design of the study, thus focusing on the methodology and operational aspects of the clinical trial. (Clinicaltrials.gov number. NCT00321893).
Authors: Hyun Ju Lee; Jin Mo Goo; Chang Hyun Lee; Chang Min Park; Kwang Gi Kim; Eun-Ah Park; Ho Yun Lee Journal: Eur Radiol Date: 2008-10-17 Impact factor: 5.315
Authors: Remco M van den Berg; H Jelle Teertstra; Nico van Zandwijk; Harm van Tinteren; Christien Visser; Arifa Pasic; Thomas G Sutedja; Paul Baas; Richard P Golding; Pieter E Postmus; Egbert F Smit Journal: Lung Cancer Date: 2007-11-05 Impact factor: 5.705
Authors: Giuseppe Pelosi; Angelica Sonzogni; Giulia Veronesi; Elisa De Camilli; Patrick Maisonneuve; Lorenzo Spaggiari; Michela Manzotti; Michele Masullo; Giulio Taliento; Caterina Fumagalli; Massimo Bellomi; William D Travis; Maryam Kadivar; Giuseppe Viale Journal: Lung Cancer Date: 2008-05-02 Impact factor: 5.705
Authors: J S Lee; S M Lippman; S E Benner; J J Lee; J Y Ro; J M Lukeman; R C Morice; E J Peters; A C Pang; H A Fritsche Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Giulia Veronesi; Massimo Bellomi; James L Mulshine; Giuseppe Pelosi; Paolo Scanagatta; Giovanni Paganelli; Patrick Maisonneuve; Lorenzo Preda; Francesco Leo; Raffaella Bertolotti; Piergiorgio Solli; Lorenzo Spaggiari Journal: Lung Cancer Date: 2008-03-04 Impact factor: 5.705
Authors: Giulia Veronesi; Eva Szabo; Andrea Decensi; Aliana Guerrieri-Gonzaga; Massimo Bellomi; Davide Radice; Stefania Ferretti; Giuseppe Pelosi; Matteo Lazzeroni; Davide Serrano; Scott M Lippman; Lorenzo Spaggiari; Angela Nardi-Pantoli; Sergio Harari; Clara Varricchio; Bernardo Bonanni Journal: Cancer Prev Res (Phila) Date: 2010-12-16
Authors: Alissa K Greenberg; Jun-Chieh Tsay; Kam-Meng Tchou-Wong; Anna Jorgensen; William N Rom Journal: Cancers (Basel) Date: 2013-01-24 Impact factor: 6.639